EGFR and non-small cell lung carcinoma: In the treatment of NSCLC, the most commonly used drug is gefitinib, which is used as an EGF receptor tyrosine kinase (EGFR-TKIS) inhibitor to treat NSCLC patients sensitive to EGFR through targeted therapy.